November 22nd 2024
With FDA's clearance, Kedrion can manufacture Ryplazim (plasminogen, human-tvmh), the first and only FDA-approved therapy for treating PLGD-1, at its Bolognana, Italy, site.
November 22nd 2024
November 15th 2024
The digital transformation of quality-by-design assessment workflows can improve efficiency, reduce human errors, and facilitate integration within a much broader digital ecosystem.
FDA Gains Approval to Revamp New Drug Review Operations
September 27th 2019After months of planning and explaining, Janet Woodcock, director of the Center for Drug Evaluation and Research (CDER), finally gained approval for broad changes in its process and procedures for evaluating and approving new drugs.
New Virtual Reality Platform Offers Life Sciences Industry Training
September 27th 2019A new educational platform by Quality Executive Partners offers on-demand digital courses with technical content, virtual reality, and real-time coaching with an initial focus on sterile product manufacturing and microbiology.
CHMP Grants Positive Opinion for Pfizer/Merck KGaA Cancer Drug Plus Axitinib for Kidney Cancer
September 23rd 2019The Committee for Medicinal Products for Human Use of the European Medicines Agency has granted a positive opinion recommending marketing authorization for Bavencio (avelumab) in combination with axitinib for treating kidney cancer.
Merck & Co.’s Application for Ebola Vaccine Accepted by FDA and Granted Priority Review
September 19th 2019In parallel to the priority review designation for its biologics license application, Merck plans to scale up its doses of the investigational Ebola vaccine to meet global outbreak response needs.